Recent developments with Mineralys Therapeutics Inc (MLYS) have led to the company’s beta value being reach -0.31 cents.
On Tuesday, Mineralys Therapeutics Inc (NASDAQ: MLYS) was -7.49% drop from the session before settling in for the closing price of $15.63. A 52-week range